Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - doxycycline hyclate, quantity: 116.3 mg (equivalent: doxycycline, qty 100 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; purified water; hypromellose phthalate; povidone; diethyl phthalate; magnesium stearate; wheat starch; hypromellose; lactose monohydrate; hyprolose; gelatin; ethanol; shellac; pharmaceutical glaze; carbon black - doxycycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. doxycycline is active against a wide range of gram-positive and gram-negative organisms. note: the 50 mg capsule is not a paediatric formulation. mayne pharma doxycycline capsules are indicated in the treatment of infections caused by the following micro-organisms: mycoplasma pneumoniae: primary atypical pneumonia. rickettsiae: queensland tick typhus, typhus fever and q fever. agents of psittacosis. calymmatobacterium (donovania) granulomitis: granuloma inguinale. agents of lymphogranuloma venereum. borreliae: relapsing fever. chlamydia trachomatis. mayne pharma doxycycline capsules are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline capsules alone, or in combination with topical agents. mayne pharma doxycycline is indicated in the treatment of infections caused by the following gram-negative micro-organisms: vibrio species: cholera. brucella species: brucellosis (in conjunction with streptomycin). yersinia pestis: plague. francisella tularensis: tularemia. bartonella bacilliformis: bartonellosis. bacteroides species. when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: treponema pallidum: syphilis. treponema pertenue: yaws. neisseria gonorrhoea: gonorrhoea (see dosage and administration). mayne pharma doxycycline capsules is not the drug of choice in the treatment of any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis, or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory tract infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever) penicillin is the usual drug of choice. doxycycline is active against both pre-erythroycitic and asexual bloodstages of plasmodium falciparum. the tetracyclines are only partially active against the pre-erythrocytic stages of plasmodium vivax and protection depends on drug suppression of the blood stages. doxycycline has no activity against the relapsing forms (hypnozoites) of plasmodium vivax. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p. vivax. as there are relatively few locations where p. vivax does not co-exist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine. in acute intestinal amoebiasis mayne pharma doxycycline capsules may be a useful adjunct to amoebicides. in severe acne mayne pharma doxycycline capsules may be a useful adjunctive therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - doxycycline hyclate, quantity: 58.15 mg (equivalent: doxycycline, qty 50 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; hypromellose phthalate; hypromellose; hyprolose; povidone; wheat starch; diethyl phthalate; purified water; gelatin; ethanol; shellac; pharmaceutical glaze; carbon black - doxycycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. doxycycline is active against a wide range of gram-positive and gram-negative organisms. note: the 50 mg capsule is not a paediatric formulation. mayne pharma doxycycline capsules are indicated in the treatment of infections caused by the following micro-organisms: mycoplasma pneumoniae: primary atypical pneumonia. rickettsiae: queensland tick typhus, typhus fever and q fever. agents of psittacosis. calymmatobacterium (donovania) granulomitis: granuloma inguinale. agents of lymphogranuloma venereum. borreliae: relapsing fever. chlamydia trachomatis. mayne pharma doxycycline capsules are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline capsules alone, or in combination with topical agents. mayne pharma doxycycline is indicated in the treatment of infections caused by the following gram-negative micro-organisms: vibrio species: cholera. brucella species: brucellosis (in conjunction with streptomycin). yersinia pestis: plague. francisella tularensis: tularemia. bartonella bacilliformis: bartonellosis. bacteroides species. when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: treponema pallidum: syphilis. treponema pertenue: yaws. neisseria gonorrhoea: gonorrhoea (see dosage and administration). mayne pharma doxycycline capsules is not the drug of choice in the treatment of any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis, or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory tract infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever) penicillin is the usual drug of choice. doxycycline is active against both pre-erythroycitic and asexual bloodstages of plasmodium falciparum. the tetracyclines are only partially active against the pre-erythrocytic stages of plasmodium vivax and protection depends on drug suppression of the blood stages. doxycycline has no activity against the relapsing forms (hypnozoites) of plasmodium vivax. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p. vivax. as there are relatively few locations where p. vivax does not co-exist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine. in acute intestinal amoebiasis manye pharma doxycycline capsules may be a useful adjunct to amoebicides. in severe acne mayne pharma doxycycline capsules may be a useful adjunctive therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - doxycycline monohydrate, quantity: 52.05 mg (equivalent: doxycycline, qty 50 mg) - tablet, uncoated - excipient ingredients: hydrogenated castor oil; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; povidone; sodium starch glycollate - infections caused by the following micro-organisms: mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always elminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline, or in combination with topical agents.) borreliae (relapsing fever); calymmatobacterium (donovania) granulomatis (granuloma inguinale). infections caused by the following gram-negative micro-organisms: vibrio sp. (cholera); brucella sp. (brucellosis; in conjunction with streptomycin); yersinia pestis (plague); francisella tularensis (tularaemia); bartonella bacilliformis (bartonellosis); bacteriodes sp. when penicillin is contraindicated, doxycycline

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxycycline monohydrate, quantity: 52.05 mg (equivalent: doxycycline, qty 50 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; hydrogenated castor oil; povidone - infections caused by the following micro-organisms: mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always elminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline, or in combination with topical agents.) borreliae (relapsing fever); calymmatobacterium (donovania) granulomatis (granuloma inguinale). doxycycline sandoz is indicated for the treatment of anthrax due to bacillus anthracis, including inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis (see dosage and administration). infections caused by the following gram-negative micro-organisms: vibrio sp. (cholera); brucella sp. (brucellosis; in conjunction with streptomycin); yersinia pestis (plague); francisella tularensis (tularaemia); bartonella bacilliformis (bartonellosis); bacteriodes sp. when penicillin is contraindicated, doxycycline is an alternative medicine in the treatment of infections due to: treponema pallidum (syphilis); treponema pertenue (yaws); neisseria gonorrhoea (see dosage and administration). note: doxycycline sandoz is not the medicine of choice in the treatment of any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline sandoz should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual medicine of choice. in acute intestinal amoebiasis doxycycline sandoz may be a useful adjunct to amoebicides. in severe acne doxycycline may be a useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by plasmodium vivax. as there are relatively few locations where p. vivax does not coexist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxycycline monohydrate, quantity: 104.1 mg (equivalent: doxycycline, qty 100 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; hydrogenated castor oil; povidone; magnesium stearate - infections caused by the following micro-organisms: mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always elminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline, or in combination with topical agents.) borreliae (relapsing fever); calymmatobacterium (donovania) granulomatis (granuloma inguinale). doxycycline sandoz is indicated for the treatment of anthrax due to bacillus anthracis, including inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis (see dosage and administration). infections caused by the following gram-negative micro-organisms: vibrio sp. (cholera); brucella sp. (brucellosis; in conjunction with streptomycin); yersinia pestis (plague); francisella tularensis (tularaemia); bartonella bacilliformis (bartonellosis); bacteriodes sp. when penicillin is contraindicated, doxycycline is an alternative medicine in the treatment of infections due to: treponema pallidum (syphilis); treponema pertenue (yaws); neisseria gonorrhoea (see dosage and administration). note: doxycycline sandoz is not the medicine of choice in the treatment of any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline sandoz should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual medicine of choice. in acute intestinal amoebiasis doxycycline sandoz may be a useful adjunct to amoebicides. in severe acne doxycycline may be a useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by plasmodium vivax. as there are relatively few locations where p. vivax does not coexist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - doxycycline hyclate, quantity: 57.5 mg (equivalent: doxycycline, qty 50 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; sunset yellow fcf; quinoline yellow; macrogol 4000 - note: the 50mg tablet is not a paediatric formulation. doxycycline is indicated in the treatment of infections caused by the following microorganisms: mycoplasma pneumoniae: primary atypical pneumonia; rickettsiae: queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus; chlamydia psittaci: psittacosis; calymmatobacterium (donovania) granulomatis: granuloma inguinale; chlamydia trachomatis: lymphogranuloma venereum, trachoma, inclusion conjunctivitis (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline alone or in combination with topical agents.); doxycycline is indicated in the treatment of infections caused by the following gram-negative microorganisms: vibrio species: cholera; brucella species: brucellosis (in conjunction with streptomycin); yersinia pestis: plague; francisella tularensis: tularaemia; bartonella bacilliformis: bartonellosis; bacteroides species. doxycycline is active against both pre-erythrocytic and asexual bloodstages of plasmodium falciparum. the tetracyclines are only partially active against the pre-erythrocytic stages of plasmodium vivax, and protection depends on drug suppression of the blood stages. doxycycline has no activity against the relapsing forms (hypnozoites) of plasmodium vivax. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p.vivax. as there are relatively few locations where p.vivax does not co-exist to some extent with p.falciparum, it is recommended that doxycycline should be used routinely with other agents, eg. chloroquine. when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: treponema pallidum: syphilis; treponema pertenue: yaws; neisseria gonorrhoeae: gonorrhoea. doxycycline may be a useful adjunct to amoebicides in the treatment of acute intestinal amoebiasis. in the treatment of severe acne, doxycycline may be a useful adjunctive therapy. doxycycline is not the drug of choice in the following: any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, enterococcus faecalis, or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxylin should not be used for these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a b-haemolytic streptococci, (including prophylaxis of rheumatic fever), penicillin is the usual drug of choice.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - doxycycline hyclate, quantity: 115 mg (equivalent: doxycycline, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; pregelatinised maize starch; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; sunset yellow fcf; quinoline yellow; macrogol 4000 - doxycycline is indicated in the treatment of infections caused by the following microorganisms: mycoplasma pneumoniae: primary atypical pneumonia; rickettsiae: queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus; chlamydia psittaci: psittacosis; calymmatobacterium (donovania) granulomatis: granuloma inguinale; chlamydia trachomatis: lymphogranuloma venereum, trachoma, inclusion conjunctivitis (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline alone or in combination with topical agents.); doxycycline is indicated in the treatment of infections caused by the following gram-negative microorganisms: vibrio species: cholera; brucella species: brucellosis (in conjunction with streptomycin); yersinia pestis: plague; francisella tularensis: tularaemia; bartonella bacilliformis: bartonellosis; bacteroides species. doxycycline is active against both pre-erythrocytic and asexual bloodstages of plasmodium falciparum. the tetracyclines are only partially active against the pre-erythrocytic stages of plasmodium vivax, and protection depends on drug suppression of the blood stages. doxycycline has no activity against the relapsing forms (hypnozoites) of plasmodium vivax. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p.vivax. as there are relatively few locations where p.vivax does not co-exist to some extent with p.falciparum, it is recommended that doxycycline should be used routinely with other agents, eg. chloroquine. when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: treponema pallidum: syphilis; treponema pertenue: yaws; neisseria gonorrhoeae: gonorrhoea. doxycycline may be a useful adjunct to amoebicides in the treatment of acute intestinal amoebiasis. in the treatment of severe acne, doxycycline may be a useful adjunctive therapy. doxycycline is not the drug of choice in the following: any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, enterococcus faecalis, or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxylin should not be used for these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a b-haemolytic streptococci, (including prophylaxis of rheumatic fever), penicillin is the usual drug of choice.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - doxycycline hyclate, quantity: 57.7 mg (equivalent: doxycycline, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; macrogol 4000 - infections caused by the following microorganisms: mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus): chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline alone or in combination with topical agents). borreliae (relapsing fever); calymmatobacterium (donovania) granulomatis (granuloma inguinale). infections caused by the following gram-negative microorganisms: vibrio sp. (cholera); brucella sp. (brucellosis, in conjunction with streptomycin); haemophilus ducreyi (chancroid); yersinia pestis (plague); francisella tularensis (tularaemia); bartonella bacilliformis (bartonellosis); bacteroides sp. when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: treponema pallidum (syphilis); treponema perenue (yaws); neisseria gonorrhoea (see dosage and administration). doxycycline is not the drug of choice in the treatment of any type of staphylococcal infection of infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, enterococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a b-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual drug of choice. in acute intestinal amoebiasis doxycycline may be a useful adjunct to amoebicides. in severe acne, doxycycline may be a useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p. vivax. as there are relatively few locations where p. vivax does not co-exist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine. note: the 50mg tablet is not a paediatric formulation.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - doxycycline hyclate, quantity: 115.4 mg (equivalent: doxycycline, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; macrogol 4000 - infections caused by the following organisms; mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline alone, or in combination with topical agents). borreliae (relapsing fever). calymmatobacterium (donovania) granulomatis (granuloma inguinale). infection caused by the following gram-negative microorganisms: vibrio species (chlorea), brucella sp. (brucellosis; in conjunction with streptomycin), haemophilus ducreyi (chancroid), yersinia pestis (plague), francisella turarenis (tularaemia), bartonella bacilliformis (bartonellosis), bacteroides sp. when penicillin is contraindicated, doxy-100 is an alternative drug in the treatment of infections due to : treponema pallidum (syphilis); treponema pertenue (yaws); neisseria gonorrhoea (see dosage and administration). doxy-100 is not the drug of choice in the treatment of any type of staphylococcal infection or infections due to streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxy-100 should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual drug of choice. in acute intestinal amoebiasis, doxycycline may be a useful adjunct to amoebicides. in severe acne, doxycycline may be useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p. vivax. as there are relatively few locations where p. vivax does not co-exist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example, chloroquine.

Malta - English - Medicines Authority

delorbis pharmaceuticals limited 17 athinon str, ergates industrial area, 2643 ergates, po box 28629, 2081 lefkosia, cyprus - minocycline - hard capsule - minocycline 50 mg - antibacterials for systemic use